Nevertheless, there is compelling evidence which indicates that patients with inflammatory forms of arthritis can become unresponsive or refractory to the currently available conventional DMARDs and/or biologic DMARDs and develop serious side-effects including neutropenia, auto-antibodies, antiidiotypic antibodies (even to some anti-TNF-α or anti-IL-6R monoclonal antibodies characterized as fully humanized) as well as reactivation and/or the onset of new bacterial infections especially at higher than recommended anti-TNF-α doses which may require withdrawing the drug [4, 19–24]. Here, IL6R is linked to arthritic joint disease.